Mural Oncology (MURA) Stock Price, News & Analysis

Company Overview

Mural Oncology, Inc. (NASDAQ: MURA) is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for cancer. The company’s research emphasizes targeting the tumor microenvironment and stromal resistance mechanisms to enhance the efficacy of existing and novel oncology agents.

Mural’s pipeline features small-molecule programs designed to inhibit signaling pathways involved in tumor growth and extracellular matrix remodeling. Its lead candidates are advancing through early-phase clinical trials in various solid tumors, leveraging translational biology tools such as patient-derived models and molecular profiling to guide drug discovery and patient selection.

Headquartered in San Mateo, California, Mural Oncology conducts research and development in the United States and collaborates with academic institutions and industry partners to support global clinical development. The company’s interdisciplinary team combines expertise in oncology research, drug development and translational science to address unmet needs across multiple cancer indications.

Key Stats

• Today's Range: $2.07 to $2.08
• 50-Day Range: $1.55 to $2.59
• 52-Week Range: $0.95 to $4.74
• Volume: 271,100 shs
• Average Volume: 531,005 shs
• Market Capitalization: $35.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Mural Oncology Stock Analysis - MarketRank™

Mural Oncology scored higher than 67% of companies evaluated by MarketBeat, and ranked 335th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mural Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Mural Oncology has a consensus price target of $12.00, representing about 479.7% upside from its current price of $2.07.

Amount of Analyst Coverage

Mural Oncology has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mural Oncology are expected to grow in the coming year, from ($7.54) to ($4.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mural Oncology is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mural Oncology is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mural Oncology has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.64% of the float of Mural Oncology has been sold short.

Short Interest Ratio / Days to Cover

Mural Oncology has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mural Oncology has recently decreased by 18.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mural Oncology does not currently pay a dividend.

Dividend Growth

Mural Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.64% of the float of Mural Oncology has been sold short.

Short Interest Ratio / Days to Cover

Mural Oncology has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mural Oncology has recently decreased by 18.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mural Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,730.00 in company stock.

Percentage Held by Insiders

Only 2.20% of the stock of Mural Oncology is held by insiders.

Percentage Held by Institutions

80.21% of the stock of Mural Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MURA Stock Analysis - Frequently Asked Questions

How have MURA shares performed this year?

Mural Oncology's stock was trading at $3.22 on January 1st, 2025. Since then, MURA stock has decreased by 35.7% and is now trading at $2.07.

How were Mural Oncology's earnings last quarter?

Mural Oncology PLC (NASDAQ:MURA) posted its earnings results on Monday, August, 4th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by $0.64.

Who are Mural Oncology's major shareholders?

Mural Oncology's top institutional shareholders include Soleus Capital Management L.P. (7.64%), Acorn Capital Advisors LLC (3.77%), Orbimed Advisors LLC (3.40%) and LMR Partners LLP (2.98%). Insiders that own company stock include Caroline Loew and Adam D Cutler.
View institutional ownership trends.

How do I buy shares of Mural Oncology?

Shares of MURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mural Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mural Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), GE Aerospace (GE) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MURA
• Previous Symbol: NASDAQ:MURA
• CIK: 1971543
• Web: www.muraloncology.com
• Phone: 353-1-905-8020
• Fax: N/A
• Employees: 119
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Mural Oncology: $12.00
• High Price Target: $18.00
• Low Price Target: $6.00
• Potential Upside/Downside: +479.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$128.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -107.76%
• Return on Assets: -87.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.87
• Quick Ratio: 2.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.22 per share
• Price / Book: 0.25

Miscellaneous

• Outstanding Shares: 17,320,000
• Free Float: 16,943,000
• Market Cap: $35.85 million
• Optionable: Optionable
• Beta: 2.99